AbbVie, along with EA Pharma, a subsidiary of Japanese pharmaceutical company Eisai, will begin the co-promotion of fully human anti-TNF-alpha monoclonal antibody Humira for indications in the field of gastrointestinal diseases.

Humira is a fully human, anti-tumour necrosis factors (TNF)-alpha monoclonal antibody.

EA Pharma was established in April this year through the integration of Eisai’s gastrointestinal disease business, and along with Ajinamoto Pharmaceuticals, is a gastrointestinal specialty pharmaceutical firm with a full value chain including research and development, production and logistics, and sales and marketing.

Eisai has assigned the responsibility to EA Pharma to undertake co-promotion on gastrointestinal disease indications for Humira with Abbvie.

"Eisai has assigned the responsibility to EA Pharma to undertake co-promotion on gastrointestinal disease indications for Humira with Abbvie."

There will be no change to the distribution and sales framework for Humira, as AbbVie will continue to be the marketing and manufacturing authorisation holder for Humira, while Eisai is responsible for its distribution.

AbbVie and Eisai will continue the co-promotion for Humira of indications outside of the gastrointestinal disease field such as the treatment of rheumatoid arthritis, including prevention of structural joint damage.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Humira will also be used for diseases that do not sufficiently respond to existing treatments.

The diseases include psoriasis vulgaris, arthropathic psoriasis, ankylosing spondylitis, and polyarticular juvenile idiopathic arthritis.

The three companies will continue to promote and provide data on the proper use of Humira, while making further contributions to improve the patients’ quality of life.